Cell Reports (Mar 2023)

IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii

  • Joseph T. Clark,
  • Orr-El Weizman,
  • Daniel L. Aldridge,
  • Lindsey A. Shallberg,
  • Julia Eberhard,
  • Zachary Lanzar,
  • Devon Wasche,
  • John D. Huck,
  • Ting Zhou,
  • Aaron M. Ring,
  • Christopher A. Hunter

Journal volume & issue
Vol. 42, no. 3
p. 112147

Abstract

Read online

Summary: Interleukin-18 (IL-18) promotes natural killer (NK) and T cell production of interferon (IFN)-γ, a key factor in resistance to Toxoplasma gondii, but previous work has shown a limited role for endogenous IL-18 in control of this parasite. Although infection with T. gondii results in release of IL-18, the production of IFN-γ induces high levels of the IL-18 binding protein (IL-18BP). Antagonism of IL-18BP with a “decoy-to-the-decoy” (D2D) IL-18 construct that does not signal but rather binds IL-18BP results in enhanced innate lymphoid cell (ILC) and T cell responses and improved parasite control. In addition, the use of IL-18 resistant to IL-18BP (“decoy-resistant” IL-18 [DR-18]) is more effective than exogenous IL-18 at promoting innate resistance to infection. DR-18 enhances CD4+ T cell production of IFN-γ but results in CD4+ T cell-mediated pathology. Thus, endogenous IL-18BP restrains aberrant immune pathology, and this study highlights strategies that can be used to tune this regulatory pathway for optimal anti-pathogen responses.

Keywords